ZENOTECH LABORATORIES LTD.

Zenotech Laboratories Ltd has announced that its Board of Directors will convene on October 28, 2026. The primary agenda item is to consider and approve the unaudited standalone financial results for the quarter and half-year ended September 30, 2026. The trading window for the company's shares will remain closed from October 1, 2026, until 48 hours after the declaration of these financial results, extending up to October 30, 2026.

Zenotech Laboratories Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading. The trading window will be shut from Thursday, October 01, 2026, and will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter and half-year ending September 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately. This measure is standard practice to prevent potential insider trading before the public disclosure of financial information.

Zenotech Laboratories Ltd held its 37th Annual General Meeting (AGM) on September 25, 2026, via video conferencing. The company announced that all resolutions presented at the AGM were approved by the shareholders with the requisite majority. This includes the adoption of the audited standalone financial statements for the fiscal year ended March 31, 2026, the re-appointment of Mr. Jignesh Anantray Goradia, and approval for material related party transactions with Sun Pharmaceutical Industries Limited. The voting results, including remote e-voting and e-voting during the AGM, were submitted along with the Scrutinizer's Consolidated Report.

Zenotech Laboratories Ltd. has announced its 37th Annual General Meeting (AGM) scheduled for Friday, September 25, 2026, at 10:30 AM IST, to be conducted via Video Conferencing. The company has also released its Annual Report for the Financial Year 2025-26. Key dates for shareholders include a cut-off date of September 18, 2026, for voting eligibility, with remote e-voting commencing on September 22, 2026, and concluding on September 24, 2026. The Annual Report and AGM notice are available on the company's website.

Zenotech Laboratories Ltd has filed its Annual Report for the Financial Year 2025-26 and the Notice of its 37th Annual General Meeting (AGM). The AGM is scheduled for Friday, September 25, 2026, at 10:30 AM IST, to be conducted entirely through Video Conferencing. Key dates include a cut-off date of September 18, 2026, for voting eligibility, with remote e-voting commencing on September 22, 2026, and concluding on September 24, 2026. The report and notice are available on the company's website. The agenda includes the adoption of audited standalone financial statements and the re-appointment of a director.

Zenotech Laboratories Ltd has announced its 37th Annual General Meeting (AGM) will be conducted on Friday, September 25, 2026, commencing at 10:30 a.m. IST. The meeting will be held entirely through Video Conferencing. This follows a previous communication dated July 28, 2026. The company will release its Annual Report and the Notice of the AGM in due course, detailing procedures for e-voting, email/mobile updates, and attending the virtual meeting. Shareholders eligible to vote or attend the AGM must be registered by the 'Cut-off Date' of Friday, September 18, 2026.

Zenotech Laboratories Ltd announced the outcome of its Board Meeting held on July 28, 2026. The Board approved the Unaudited Standalone Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report from the Statutory Auditors. Additionally, the Board approved the convening of the 37th Annual General Meeting (AGM) to be held on September 25, 2026, at 10:30 A.M. IST through Videoconferencing. The notice of the AGM and the Annual Report will be released in due course.

Zenotech Laboratories, reporting standalone-only figures (it has no subsidiaries, JVs or associates under Ind AS 110 — its overseas units are defunct or wound up), posted revenue from operations of ₹9.60 Cr in Q1 FY27, up 11.1% YoY from ₹8.64 Cr and 8.3% QoQ from ₹8.87 Cr in Q4 FY26. Despite the topline growth, the company swung to a net loss of ₹0.46 Cr (basic EPS -₹0.07) against a profit of ₹0.99 Cr (EPS ₹0.16) in the year-ago quarter — the primary YoY signal is a reversal from profit to loss, not the revenue gain. Sequentially the loss narrowed sharply, down 86% from Q4 FY26's ₹3.15 Cr loss. The YoY swing was driven by cost growth outrunning revenue: employee benefit expense rose 39% YoY to ₹4.92 Cr (₹3.54 Cr) and other expenses rose 32% YoY to ₹4.83 Cr (₹3.65 Cr), lifting total expenses 30% YoY to ₹11.65 Cr against just 11% revenue growth. Net margin (PAT/total income) compressed to -4.1% from +9.7% a year ago, though it improved from -30.1% in Q4 FY26 — Q4's deeper loss was itself inflated by a one-off ₹2.39 Cr prior-period tax charge not repeated this quarter. This quarter carried no exceptional item (Q4 FY26 had a ₹0.05 Cr exceptional gain), and a ₹0.15 Cr net deferred-tax credit narrowed the pretax loss of ₹0.60 Cr to the ₹0.46 Cr net loss. There is no management guidance on record from prior quarters and none disclosed in this filing, so the print cannot be graded against a stated outlook; a web search found no analyst previews or consensus estimates for this stock either, consistent with it being a micro-cap with negligible coverage. The filing itself contains no separate press release or management commentary beyond the regulatory outcome letter and standard notes — there is no company framing of the quarter to reconcile against the numbers. The only corporate development in the window was procedural: the July 13, 2026 board-meeting intimation and the June 30 trading-window closure ahead of this result, plus the now-approved 37th AGM (September 25, 2026); none bear directly on the operating numbers. Going into Q2 FY27, the trend to watch is whether revenue growth can outpace the employee-cost inflation that drove this quarter's YoY swing to loss, and whether the sequential loss-narrowing (₹3.15 Cr to ₹0.46 Cr over two quarters) continues or was partly a function of the tax credit and absence of one-off charges this quarter.

Zenotech Laboratories Ltd has announced that its Board of Directors will convene on Tuesday, July 28, 2026. The primary agenda item is to consider and approve the Unaudited Standalone Financial Results for the quarter ended June 30, 2026. Additionally, the company has confirmed the closure of its trading window from July 1, 2026, to July 30, 2026, which will reopen after 48 hours of the financial results declaration.

Zenotech Laboratories Ltd has announced the closure of its trading window for dealing in the company's shares. This closure will be effective from Wednesday, July 01, 2026, and will remain in effect for 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately. This measure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading, aimed at preventing potential misuse of unpublished price-sensitive information.